Skip to content
Peptigraph home

CJC-1295 + Ipamorelin and Retatrutide Together: What Is Known

CJC-1295 + Ipamorelin and Retatrutide taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH + GHRP blendNot FDA approved · research blendCJC-1295 + IpamorelinUnapproved blend of CJC-1295 (no DAC) and ipamorelin; an FDA Drugs@FDA search for the CJC-1295 component returned no matches, so no approved product was found.[14]Growth hormoneGLP-1 / GIP / glucagon triple agonistInvestigational · phase 3RetatrutideInvestigational triple GIP, GLP-1 and glucagon receptor agonist, not FDA-approved; a phase 3 TRIUMPH trial reported mean weight change of -25.0% at the 12-mg dose versus -3.9% with placebo.[1]GLP-1 & metabolic
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 0 results, 2 Oct 2026).

Neither is FDA approved for use in people, and we have no sourced data on combining them.
Each component

Side by side

Showing 11 of 13 fields where the two differ. PCAC vote, Jul 2026, Evidence strength are the same or both unknown.

FieldCJC-1295 + IpamorelinRetatrutide
ClassGHRH + GHRP blendGLP-1 / GIP / glucagon triple agonist
Also calledCJC/Ipareta, GLP-3, LY3437943
CategoryGrowth hormoneGLP-1 & metabolic
FDA statusNot FDA approved · research blendInvestigational · phase 3
WADAProhibited by WADA (S2.2.4)Both components are named in S2.2.4 (CJC-1295 as a GHRH analogue, ipamorelin as a secretagogue), so the blend is prohibited at all times.Prohibited by WADA (S0)Retatrutide is not named, and GLP-1/amylin class agonists are not listed. But it is an investigational drug with no approval in the sources we reviewed, and S0 prohibits drugs under clinical development that no authority has approved. If it is approved somewhere this would change.
Anti-doping detection
  • After nasal dosing, ipamorelin metabolites were still found in urine after the parent drug was gone (samples were collected for 2 days).PMID 25869809
None reportedanti-doping literature, as of 2 Oct 2026
Half-lifeIpamorelin: 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658approximately 6 dayssubcutaneous · Lancet 2022, PMID 36354040
Human studies we summarised6 human (3 randomized or controlled) of 19 summarised, across ingredients11 human (11 randomized or controlled) of 16 summarised
Typical study doses
Vial sizes sold10 mg5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 24 mg, 30 mg, 36 mg, 40 mg, 50 mg, 60 mg
Named in FDA warning letters, 2026Not in the letters we trackYes (24 Aug 2026; 31 Mar 2026)

What is known about the blend and its parts

Drugs@FDA returns no match for CJC-1295, one of the blend's components.[14]

CJC-1295 raised GH 2- to 10-fold for 6 d or more after one injection in healthy volunteers.[9]

Ipamorelin was tested in a placebo-controlled trial in patients recovering from bowel surgery, where it did not significantly shorten time to the first tolerated meal.[8]

Retatrutide

Drugs@FDA returns no match for retatrutide.[15]

In the large phase 3 obesity trial, mean weight change was -17.6% on 4 mg, -23.7% on 9 mg and -25.0% on 12 mg versus -3.9% on placebo.[1]

Adverse events in retatrutide trials

In the phase 2 trial the most common retatrutide adverse events were gastrointestinal, dose-related, mostly mild to moderate and partially mitigated with a lower starting dose (2 mg vs. 4 mg).[16]

The heart-rate increases peaked at 24 weeks and declined thereafter.[16]

Which CJC-1295 do the human data cover?

One review of GH-axis peptides lists CJC-1295 with DAC and CJC-1295 without DAC as separate agents.[17]

A GH-pulsatility paper describes the albumin-binding analogue with a half-life of 8 d.[18]

Any study of the combination?

The search for the blend and retatrutide returned 0 PubMed records.

Calculated from pubmed query (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND (retatrutide[tiab] OR LY3437943[tiab]); search date 2026-10-02; records returned 0; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key cjc-1295-ipamorelin__retatrutide); no arithmetic applied.

On WADA's prohibited list, CJC-1295 is named under GHRH analogues.[5]

Common questions

Can you stack CJC-1295/ipamorelin with retatrutide?

The cached PubMed search for the blend with retatrutide returned 0 records.

Calculated from records returned 0; search date 2026-10-02. Formula: Counts copied from the combinations dataset (key cjc-1295-ipamorelin__retatrutide); no arithmetic applied.

CJC-1295/ipamorelin vs retatrutide: which has human weight data?

Retatrutide does, in randomized trials; the blend has no weight trial, and its ipamorelin component was tested for bowel recovery after surgery.[8]

Sources

  1. 1Retatrutide phase 3 TRIUMPH-1 results publishedNEJM (PubMed 42814954) · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  2. 2FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  3. 3Eli Lilly sues six retatrutide sellersEli Lilly (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
  4. 4Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  5. 5World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  6. 6Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
  7. 7Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
  8. 8Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
  9. 9Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  10. 10LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
  11. 11Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes, obesity & metabolism · 2026PMID 42608321Accessed 2 Oct 2026
  12. 12Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.The lancet. Diabetes & endocrinology · 2025PMID 40609566Accessed 2 Oct 2026
  13. 13PubMed search: (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND (retatrutide[tiab] OR LY3437943[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  15. 15Drugs@FDA (openFDA) search: active ingredient "retatrutide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  16. 16Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine · 2023PMID 37366315Accessed 2 Oct 2026
  17. 17The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026
  18. 18Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026

Found an error? Report a correction.